Cargando…
Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine
ABSTRACT: Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. This process is one of the most important ellipticine DNA-damaging mechanisms for its antitumor action. Here, we investigated the efficiencies o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653753/ https://www.ncbi.nlm.nih.gov/pubmed/29104319 http://dx.doi.org/10.1007/s00706-017-1986-9 |
_version_ | 1783273268057210880 |
---|---|
author | Stiborová, Marie Indra, Radek Frei, Eva Kopečková, Kateřina Schmeiser, Heinz H. Eckschlager, Tomáš Adam, Vojtěch Heger, Zbyněk Arlt, Volker M. Martínek, Václav |
author_facet | Stiborová, Marie Indra, Radek Frei, Eva Kopečková, Kateřina Schmeiser, Heinz H. Eckschlager, Tomáš Adam, Vojtěch Heger, Zbyněk Arlt, Volker M. Martínek, Václav |
author_sort | Stiborová, Marie |
collection | PubMed |
description | ABSTRACT: Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. This process is one of the most important ellipticine DNA-damaging mechanisms for its antitumor action. Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b (5) reductase and/or cytochrome b (5) in Supersomes™ to oxidize this drug. We also evaluated the effectiveness of coenzymes of two of the microsomal reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of NADH:cytochrome b (5) reductase, to mediate ellipticine oxidation in these enzyme systems. Using HPLC analysis we detected up to five ellipticine metabolites, which were formed by human hepatic microsomes and human CYP3A4 in the presence of NADPH or NADH. Among ellipticine metabolites, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine were formed by hepatic microsomes as the major metabolites, while 7-hydroxyellipticine and the ellipticine N (2)-oxide were the minor ones. Human CYP3A4 in Supersomes™ generated only three metabolic products, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine. Using the (32)P-postlabeling method two ellipticine-derived DNA adducts were generated by microsomes and the CYP3A4-Supersome system, both in the presence of NADPH and NADH. These adducts were derived from the reaction of 13-hydroxy- and 12-hydroxyellipticine with deoxyguanosine in DNA. In the presence of NADPH or NADH, cytochrome b (5) stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. This heme protein also stimulated the formation of both ellipticine-DNA adducts. The results demonstrate that cytochrome b (5) plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b (5) mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b (5) reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b (5) can act as an allosteric modifier of the CYP3A4 oxygenase. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-5653753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-56537532017-11-01 Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine Stiborová, Marie Indra, Radek Frei, Eva Kopečková, Kateřina Schmeiser, Heinz H. Eckschlager, Tomáš Adam, Vojtěch Heger, Zbyněk Arlt, Volker M. Martínek, Václav Monatsh Chem Original Paper ABSTRACT: Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. This process is one of the most important ellipticine DNA-damaging mechanisms for its antitumor action. Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b (5) reductase and/or cytochrome b (5) in Supersomes™ to oxidize this drug. We also evaluated the effectiveness of coenzymes of two of the microsomal reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of NADH:cytochrome b (5) reductase, to mediate ellipticine oxidation in these enzyme systems. Using HPLC analysis we detected up to five ellipticine metabolites, which were formed by human hepatic microsomes and human CYP3A4 in the presence of NADPH or NADH. Among ellipticine metabolites, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine were formed by hepatic microsomes as the major metabolites, while 7-hydroxyellipticine and the ellipticine N (2)-oxide were the minor ones. Human CYP3A4 in Supersomes™ generated only three metabolic products, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine. Using the (32)P-postlabeling method two ellipticine-derived DNA adducts were generated by microsomes and the CYP3A4-Supersome system, both in the presence of NADPH and NADH. These adducts were derived from the reaction of 13-hydroxy- and 12-hydroxyellipticine with deoxyguanosine in DNA. In the presence of NADPH or NADH, cytochrome b (5) stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. This heme protein also stimulated the formation of both ellipticine-DNA adducts. The results demonstrate that cytochrome b (5) plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b (5) mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b (5) reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b (5) can act as an allosteric modifier of the CYP3A4 oxygenase. GRAPHICAL ABSTRACT: [Image: see text] Springer Vienna 2017-07-04 2017 /pmc/articles/PMC5653753/ /pubmed/29104319 http://dx.doi.org/10.1007/s00706-017-1986-9 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Stiborová, Marie Indra, Radek Frei, Eva Kopečková, Kateřina Schmeiser, Heinz H. Eckschlager, Tomáš Adam, Vojtěch Heger, Zbyněk Arlt, Volker M. Martínek, Václav Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine |
title | Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine |
title_full | Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine |
title_fullStr | Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine |
title_full_unstemmed | Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine |
title_short | Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine |
title_sort | cytochrome b(5) plays a dual role in the reaction cycle of cytochrome p450 3a4 during oxidation of the anticancer drug ellipticine |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653753/ https://www.ncbi.nlm.nih.gov/pubmed/29104319 http://dx.doi.org/10.1007/s00706-017-1986-9 |
work_keys_str_mv | AT stiborovamarie cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine AT indraradek cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine AT freieva cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine AT kopeckovakaterina cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine AT schmeiserheinzh cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine AT eckschlagertomas cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine AT adamvojtech cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine AT hegerzbynek cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine AT arltvolkerm cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine AT martinekvaclav cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine |